Wednesday, December 07, 2016 6:19:25 PM
Some of the highlights of the bill that are of interest to the rare disease community include:
$4.8 billion in new funding for the National Institutes of Health (NIH)
$500 million in new funding for the Food and Drug Administration (FDA)
Reauthorization of the Rare Pediatric Disease Priority Review Voucher program through 2020
Funding for the establishment of a national neurological disease surveillance system coordinated by the Centers for Disease Control and Prevention (CDC)
Improved biomarker qualification
Strengthened patient engagement at the FDA through the Patient Focused Impact Assessment Act
A regenerative medicine designation to allow such products to qualify for priority review and accelerated approval
One item that was dropped from the act was The Orphan Products Extensions Now, Accelerating Cures and Treatments (OPEN ACT) which would have provided an incentive for companies to repurpose existing drugs for rare disease indications.
http://www.raredr.com/news/senate-votes-94-4
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM